Download PDF
Aktuelle Urol 2001; 32(S1): 44-47
DOI: 10.1055/s-2001-15946
KONSERVATIVE THERAPIE
Georg Thieme Verlag Stuttgart · New York

Konservative Therapie der Induratio penis plastica

Conservative Treatment of Induratio Penis PlasticaE. W. Hauck, I. Schroeder-Printzen, W. Weidner
  • Justus-Liebig-Universität Gießen, Urologische Klinik und Poliklinik
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Dieser Beitrag gibt eine Übersicht über den aktuellen Stand der konservativen medikamentösen Therapie der Induratio penis plastica und schließt die orale und intraläsionale Pharmakaapplikation sowie die Iontophorese, die den transdermalen Wirkstofftransport verstärkt, ein. Nach den Kriterien der „evidence-based medicine” sind nur wenige Substanzen geprüft, nur zwei weisen einen Effekt bei oraler und eine bei intraläsionaler Therapie auf. Die Iontophorese wurde nur unter der Verwendung einer Wirkstoffkombination bislang erfolgreich nach harten Kriterien getestet. Weitere prospektive Studien zur Verifizierung erster Erfolge sind unbedingt erforderlich.

Abstract

This paper reviews the current status on conservative therapy of Peyronie's disease including oral and intralesional drug administration, and iontophoresis that enhances the transdermal drug transport. According to the criteria of „evidence-based medicine” only few substances have been proved, only two oral drugs and one for intralesional administration have been demonstrated to be effective. Iontophoresis has been only investigated under the application of a drug combination according to strict criteria. Further prospective studies for verification of first results urgently required.

Schlüsselwörter

Induratio penis plastica - Konservatie Therapie - Iontophorese

Key words

Peyronie's disease - Conservative Therapy - Iontophoresis

Literatur

  • 1 Gelbard M K, Dorey F, James K. The natural history of Peyronie's disease.  J Urol. 1990;  144 1376-1379
    PubMedGoogle Scholar
  • 2 Furlow W L, Swanson H E, Lee R E. Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy.  J Urol. 1975;  114 69-71
    PubMedGoogle Scholar
  • 3 Poutasse E F. Peyronie's disease.  J Urol. 1972;  107 419-422
    PubMedGoogle Scholar
  • 4 Hauck E W, Heitz M, Schreiter F, Weidner W. Induratio penis plastica.  Akt Urol. 1999;  30 386-404
    PubMedGoogle Scholar
  • 5 Zarafonetis C JD. Antifibrotic therapy with Potaba.  Am J Med Sci. 1964;  248 550-561
    PubMedGoogle Scholar
  • 6 Weidner W, Schroeder-Printzen I, Rudnick J, Krause W, Weiske W H, Drawz B, Rebmann U, Pastermadjeff L, Kallerhoff M, Lenk S, Sperling H, Kliesch S, Schnitker J, Aulitzky W. Randomized prospective plazebo-controlled therapy of Peyronie's disease (IPP) with Potaba® (Aminobenzoate potassium).  J Urol. 1999;  161 (suppl) 205 abstract 785
    PubMedGoogle Scholar
  • 7 Carson C C. Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective.  Tech Urol. 1997;  3 135-139
    PubMedGoogle Scholar
  • 8 Lemourt Oliva M, Filgueiras López E, Rodríguez Barroso A, González Oramas E, Bornonado R. Evalución clínica del uso propóleo en la enfermedad de Peyronie.  Arch Esp de Urol. 1998;  51 (suppl 2) 171-176
    PubMedGoogle Scholar
  • 9 Teloken C, Rhoden E L, Meyer Grazziotin T, Da Ros C T, Sogari P R, Vargas Souto C A. Tamoxifen versus placebo in the treatment of Peyronie's disease.  J Urol. 1999;  162 2003-2005
    PubMedGoogle Scholar
  • 10 Ralph D J, Brooks M D, Bottazo G F, Pryor J P. The treatment of Peyronie's disease with Tamoxifen.  Br J Urol. 1992;  70 648-651
    PubMedGoogle Scholar
  • 11 Apaydin E, Semerci B, Kefi A, Cikili N, Gürsan A, Mülazimoglu N. (1998) The use of Tamoxifen in the treatment of Peyronie's disease.  Int J Impotence Res. 1998;  10 (Suppl 3) S57 abstract 421
    PubMedGoogle Scholar
  • 12 Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue T F. Is colchicine effective in Peyronie's disease? A pilot study.  Urology. 1995;  44 291-295
    PubMedGoogle Scholar
  • 13 Pryor J P, Farell C R. Controlled clinical trial of vitamin E in Peyronie's disease.  Prog Reprod Biol Med. 1983;  9 41-45
    PubMedGoogle Scholar
  • 14 Levine L A, Merrick P F, Lee R C. Intralesional verapamil injection for the treatment of Peyronie's disease.  J Urol. 1994;  151 1522-1524
    PubMedGoogle Scholar
  • 15 Levine L A. Treatment of Peyronie's disease with intralesional verapamil injection.  J Urol. 1997;  158 1395-1399
    PubMedGoogle Scholar
  • 16 Levine L A, Goldman K E. Updated experience with intralesional verapamil injection treatment for Peyronie's disease.  J Urol. 2000;  163 (suppl) 170 abstract 751
    PubMedGoogle Scholar
  • 17 Teloken C, Vaccaro F, Da Ros C, Sogari P, Souto C AV. Objective evaluation of non-surgical approach for Peyronie's disease.  J Urol. 1996;  155 (suppl) 633A abstract 1290
    PubMedGoogle Scholar
  • 18 Lasser A, Vandenberg T L, Vincent M J, Hellstrom W JG. Intraplaque verapamil injection for treatment of Peyronie's diseae.  J La State Med Soc. 1998;  150 431-434
    PubMedGoogle Scholar
  • 19 Mirone V, Imbimbo C, Palmieri A, Fusco F. Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica.  Eur Urol. 1999;  36 327-330
    CrossrefPubMedGoogle Scholar
  • 20 Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study.  Urology. 1998;  51 620-626
    CrossrefPubMedGoogle Scholar
  • 21 Nicolai M, Cipollone G, Iantorno R, Mastroprimiano A Z, Tenaglia R. Intralesional verapamil injection versus placebo in Peyronie's disease.  J Urol. 1998;  159 (suppl 5) 117 abstract 450
    PubMedGoogle Scholar
  • 22 Steiger M, Ohlig W, Ludwig G. Verapamil versus Plazebo als Injektionstherapie der Induratio penis plastica: Langzeitergebnisse einer Doppel-blind-Studie.  Urologe A. 1999;  38 (suppl 1) S58 abstract V7.6
    PubMedGoogle Scholar
  • 23 Wegner H EH, Andresen R, Knispel H H, Miller K. Treatment of Peyronie's disease with local interferon-alpha2b.  Eur Urol. 1995;  28 236-240
    PubMedGoogle Scholar
  • 24 Wegner H EH, Andresen R, Knispel H H, Miller K. Local interferon-alpha2b is not an effective treatment in early-stage Peyronie's disease.  Eur Urol. 1997;  32 190-193
    PubMedGoogle Scholar
  • 25 Judge I S, Wisniewski Z S. Intralesional interferon in the treatment of Peyronie's disease: a pilot study.  Br J Urol. 1997;  79 40-42
    PubMedGoogle Scholar
  • 26 Ahuja S K, Case J, Vincent M, Sikka S C, Hellstrom W J. Intralesional injection of alpha interferon 2b in the treatment of Peyronie's disease.  J Urol. 1998;  159 (suppl) 117 abstract 452
    PubMedGoogle Scholar
  • 27 Bryan W W, Novak T E, Vincent M, Sikka S C, Templeton L E, Hellstrom W JG. Combined theray of interferon alpha 2B (Intron A), and vitamin E in the treatment of Peyronie's disease.  J Urol. 2000;  163 (suppl) 197 abstract 873
    PubMedGoogle Scholar
  • 28 Polat O, Gül O, Özbey I, Özdikici M, Bayraktar Y. Peyronie's disease: intralesional treatment with interferon-alpha2a and evaluation of the results by magnetic resonance imaging.  Int Urol Nephrol. 1997;  29 465-471
    PubMedGoogle Scholar
  • 29 Duncan M R, Berman B, Nseyo U O. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons alpha, beta and gamma.  Scand J Urol Nephrol. 1991;  141 81-94
    PubMedGoogle Scholar
  • 30 Gelbard M K, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study.  J Urol. 1993;  149 56-58
    PubMedGoogle Scholar
  • 31 Pastorini S, Marino G, Brigato R, Griffa D, Cocimano V. La terapia dell'IPP con superossidismutasi per os e iniettiva associata a FIC vasoattiva.  Minerva Urol Nefrol. 1991;  43 75-78
    PubMedGoogle Scholar
  • 32 Primus G. Orgotein in the treatment of plastic induration of the penis (Peyronie's disease).  Int Urol Nephrol. 1993;  25 169-17
    PubMedGoogle Scholar
  • 33 Rugendorff E W. Lokalbehandlung der Induratio penis plastica.  Sexualmedizin. 1990;  19 602-608
    PubMedGoogle Scholar
  • 34 Cipollone G, Nicolai M, Mastroprimiano G, Iantorno R, Longeri D, Tenaglia R. Betametasone versus placebo nella malattia di la Peyronie.  Arch Ital Urol Androl. 1998;  70 165-168
    PubMedGoogle Scholar
  • 35 Montorsi F, Salonia A, Guazzoni G, Barbieri L, Colombo R, Brausi M, Scattoni V, Rigatti P. Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results.  J Androl. 2000;  21 85-90
    PubMedGoogle Scholar
  • 36 Treffiletti S, Annoscia S, Montefiore F, Boccafoschi C. La iontoforesi nel trattamento conservatio della malattia di La Peyronie: esperienza preliminare.  Arch It Urol. 1997;  LXIX 323-327
    PubMedGoogle Scholar
  • 37 Riedl C R, Plas E, Engelhardt P, Daha K, Pflüger H. Iontophoresis for treatment of Peyronie's disease.  J Urol. 2000;  163 95-99
    PubMedGoogle Scholar

Prof. Dr. med W Weidner

Justus-Liebig-Universität Gießen
Urologische Klinik und Poliklinik

Klinikstraße 29
35385 Gießen

Phone: Tel.: 0641-9944501

Fax: Fax: 0641-9944509

Email: E-mail: wolfgang.weidner@chiru.med.uni-gießen.de

      >